Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Legend Biotech announced positive Phase 1 clinical data for LB2501, an investigational in vivo CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The therapy achieved 100% objective response rate and 83.3% complete response rate at the higher dose level following a single infusion without lymphodepletion, with a favorable safety profile showing no dose-limiting toxicities, serious adverse events, or ICANS.